The NHS rollout of semaglutide (Wegovy) for cardiovascular risk reduction is set to become one of the largest pharmacy workforce challenges of 2026. With NICE approving its use for adults with established cardiovascular disease and a BMI of 27+, an estimated 1.2 million patients become eligible — each requiring prescribing support, monitoring, and medicines optimisation that falls squarely on pharmacy teams.
The Pharmacy Workforce Impact
GLP-1 receptor agonist prescribing is not a simple repeat prescription. Each patient requires:
- Initial clinical assessment — BMI, cardiovascular risk scoring, contraindication screening
- Dose titration — 4-month escalation from 0.25mg to maintenance dose
- Ongoing monitoring — side effect management, weight tracking, cardiovascular outcomes
- Medicines optimisation — interaction checking against existing cardiac medications
In primary care, this work increasingly falls to clinical pharmacists working in GP practices and Primary Care Networks (PCNs). PharmSee's data shows 12,858 GP practices across England, many of which now employ PCN-funded pharmacists.
Regional Demand Forecast
The regions with the highest cardiovascular disease prevalence and existing pharmacy workforce gaps will feel the squeeze most:
| Region | GP Practices (sample) | Pharmacies (sample) | GP:Pharmacy Ratio | CVD Burden |
|---|---|---|---|---|
| North East (Newcastle) | 60 | 87 | 0.69:1 | Very high |
| North West (Manchester) | 104 | 113 | 0.92:1 | High |
| West Midlands (Birmingham) | 147 | 136 | 1.08:1 | High |
| East Midlands (Nottingham) | 62 | 86 | 0.72:1 | Moderate-high |
| South West (Bristol) | 61 | 70 | 0.87:1 | Moderate |
The North East stands out: with the highest cardiovascular mortality rates in England and a GP:pharmacy ratio of just 0.69:1 around Newcastle, existing pharmacy teams are already stretched. Adding Wegovy prescribing to their workload without additional recruitment will be unsustainable.
Salary Implications
Regions under the most Wegovy-related pressure are not necessarily the highest-paying. Current PharmSee salary data shows:
| Region | Median Pharmacist Salary | Sample Size |
|---|---|---|
| North East | £32,640 | 21 |
| North West | £34,422 | 35 |
| West Midlands | £34,762 | 38 |
| National | £42,631 | 384 |
The North East's median of £32,640 — nearly £10,000 below the national median — suggests a recruitment challenge. Trusts and PCNs in high-CVD areas may need to offer premiums to attract pharmacists willing to take on the Wegovy workload.
What PCN Pharmacists Should Expect
If you're a PCN-based clinical pharmacist, Wegovy prescribing will likely become part of your role in 2026. The Primary Care Network Workforce data (due April 2026) will show how PCN pharmacy staffing has evolved, but current PharmSee data suggests:
- 1,385 active pharmacy vacancies nationally — many in primary care settings
- Boots alone has 537 openings, suggesting community pharmacy is haemorrhaging staff to NHS primary care roles
- NHS median salary of £42,631 vs community median of £32,175 — a £10,456 gap driving the migration
Explore PCN and GP practice pharmacist roles on PharmSee Jobs, and use our location analysis tool to assess pharmacy density in your area before committing to a role.
The Bigger Picture
The Wegovy rollout is a stress test for NHS pharmacy. Regions with high CVD burden, low pharmacist pay, and already-stretched pharmacy teams will struggle most. PharmSee tracks these dynamics across all 13,147 English pharmacies — explore the data on our pharmacy analytics dashboard.
Sources: Record GP access figures, Primary Care Network Workforce, 30 April 2026, NHS Staff Earnings Estimates, March 2026, PharmSee salary and job data (April 2026)